Bordeaux, France / October 11th, 2022 – TreeFrog Therapeutics, a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem™ technology platform, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using the C-Stem™ technology. [Read more…]
8th Perinatal Stem Cell Society Congress/Workshop Coming Soon
The 8th Perinatal Stem Cell Society Congress/Workshop is taking place November 3, 2022, at the Westin Beach Resort in Fort Lauderdale, FL.
$599 Early Bird Ticket Sales Close Oct. 15th
After Oct. 15th the price is $899
Please register here
As a patient advocate, my aim is to create affordable access to safe stem cell and biologic therapies in the United States. There is an opportunity to work with FDA at this time to make substantial and long-lasting changes to the IND pathways. I have called this one-day workshop so that the industry can come together, not to challenge the FDA, but to work with FDA to find solutions that will enable access to life changing therapies for patients in the U.S. [Read more…]
Exosome Industry Progress is Accelerated by Landmark Events (Timeline)
Exosomes are small vesicles that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. It has been long known that stem cells have the potential to exert therapeutic effects, but it only now being recognized that exosomes play an important role how these effects occur.
Over the past few years, this recognition has fueled a market for products and technologies leveraging stem cell exosomes. Key events in the formation of this market are highlighted in the timeline below. [Read more…]
Pluristyx, panCELLa, and Implant Therapeutics Announce Definitive Merger Agreement
Fully integrated companies streamline access to genetically modified stem cells for clinical development
October 6, 2022, Seattle, Washington – Pluristyx, panCELLa, and Implant Therapeutics management are excited to announce their corporate merger, pending shareholder approval. The merged company will combine complementary portfolios to offer end-to-end customer support and provide increased access to a wide range of induced pluripotent stem cell (iPSC)-related products and services. The integrated technological and service offerings will greatly accelerate the development and delivery of revolutionary cell therapies to patients. [Read more…]
CPD-017 by Kataoka Corporation to Streamline iPSC Processing for the US Market
Los Angeles, California, October 5, 2022 – Kataoka Corporation (Kyoto, Japan) and Kataoka-SS America Corporation (Carson, CA) have developed the CPD-017, a cell processing platform that uses cutting edge laser and AI technology to purify adherent iPSC cultures. [Read more…]
- « Previous Page
- 1
- …
- 141
- 142
- 143
- 144
- 145
- …
- 338
- Next Page »